Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers
Systemic bevacizumab is a novel targeted anti-angiogenic therapy for high-output cardiac failure (HOCF) in hereditary hemorrhagic telangiectasia (HHT) but published data is limited. This survey-based study mea...
Source: Orphanet Journal of Rare Diseases - Category: Internal Medicine Authors: Hanny Al-Samkari, Hasan A. Albitar, Scott E. Olitsky, Marianne S. Clancy and Vivek N. Iyer Tags: Research Source Type: research
More News: Avastin | Hereditary Hemorrhagic Telangiectasia | Internal Medicine | Rare Diseases | Study